OA12812A - (4-phenyl) Piperidin-3-yl-phenylcarboxylate derovatoves and related compounds as beta-secretase inhibitors for the treatment of Alzheimer's Disease. - Google Patents

(4-phenyl) Piperidin-3-yl-phenylcarboxylate derovatoves and related compounds as beta-secretase inhibitors for the treatment of Alzheimer's Disease. Download PDF

Info

Publication number
OA12812A
OA12812A OA1200400289A OA1200400289A OA12812A OA 12812 A OA12812 A OA 12812A OA 1200400289 A OA1200400289 A OA 1200400289A OA 1200400289 A OA1200400289 A OA 1200400289A OA 12812 A OA12812 A OA 12812A
Authority
OA
OAPI
Prior art keywords
alkyl
alkoxy
heteroaryl
aryl
optionally substituted
Prior art date
Application number
OA1200400289A
Other languages
English (en)
Inventor
David L Brown
Jon S Jacobs
Barbara Jagodzinska
Varghese John
Joseph B Moon
Shon R Pulley
Daniel H Rich
Original Assignee
Elan Pharm Inc
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, Upjohn Co filed Critical Elan Pharm Inc
Publication of OA12812A publication Critical patent/OA12812A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA1200400289A 2001-11-19 2002-11-19 (4-phenyl) Piperidin-3-yl-phenylcarboxylate derovatoves and related compounds as beta-secretase inhibitors for the treatment of Alzheimer's Disease. OA12812A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33270801P 2001-11-19 2001-11-19
US38316702P 2002-05-24 2002-05-24

Publications (1)

Publication Number Publication Date
OA12812A true OA12812A (en) 2006-07-10

Family

ID=26988352

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200400289A OA12812A (en) 2001-11-19 2002-11-19 (4-phenyl) Piperidin-3-yl-phenylcarboxylate derovatoves and related compounds as beta-secretase inhibitors for the treatment of Alzheimer's Disease.

Country Status (21)

Country Link
US (1) US7338965B2 (sr)
EP (1) EP1448200A2 (sr)
JP (1) JP2005514362A (sr)
KR (1) KR20050044533A (sr)
AP (1) AP2004003052A0 (sr)
AU (1) AU2002360403A1 (sr)
BR (1) BR0214295A (sr)
CA (1) CA2467749A1 (sr)
CO (1) CO5580743A2 (sr)
EA (1) EA200400699A1 (sr)
GE (1) GEP20074045B (sr)
HR (1) HRP20040550A2 (sr)
IL (1) IL162079A0 (sr)
IS (1) IS7271A (sr)
MX (1) MXPA04004772A (sr)
NO (1) NO20042580L (sr)
NZ (1) NZ533158A (sr)
OA (1) OA12812A (sr)
RS (1) RS54204A (sr)
TN (1) TNSN04088A1 (sr)
WO (1) WO2003043987A2 (sr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
MX2007012341A (es) 2005-04-08 2008-02-12 Comentis Inc Compuestos que inhiben actividad beta-secretasa y metodos de uso de los mismos.
EP1816122A3 (en) * 2006-01-19 2007-09-19 Speedel Experimenta AG 3,4,5-substituted piperidines as therapeutic compounds
CA2655933C (en) 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
KR100679869B1 (ko) * 2006-10-27 2007-02-07 한국기계연구원 Dpf시스템용 플라즈마 반응기와 이를 이용한 입자상물질의 저감 장치
CA2664130A1 (en) 2006-09-21 2008-03-27 Merck & Co., Inc. Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
KR100838645B1 (ko) * 2006-09-28 2008-06-16 한국화학연구원 베타-세크리테아제 활성을 억제하는 피페리딘 화합물
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
KR100894713B1 (ko) * 2007-10-08 2009-04-24 한국화학연구원 베타-세크리테아제의 활성을 저해하는 아릴피페라진이 치환된 피페리딘 유도체 또는 이의 약제학적으로 허용 가능한 염 및 이를 유효성분으로 함유하는 신경퇴행성 질환의 예방 또는 치료용 조성물
CN104829714A (zh) 2008-11-03 2015-08-12 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
CA2893376A1 (en) 2011-03-31 2012-10-04 Alethia Biotherapeutics Inc. Antibodies against kidney associated antigen 1 and antigen binding fragemnts thereof
AU2013209234B2 (en) 2012-01-09 2017-11-09 Adc Therapeutics Sa Method for treating breast cancer
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992441A (en) * 1972-12-26 1976-11-16 Pfizer Inc. Sulfamylbenzoic acids
US4248876A (en) * 1977-01-08 1981-02-03 John Wyeth & Brother Ltd. Piperidine derivatives
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
DE3640475A1 (de) * 1986-11-27 1988-06-09 Hoechst Sa Lab Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins, die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
IL88156A (en) * 1987-11-13 1997-02-18 Novo Nordisk As Azacyclic compounds their preparation and pharmaceutical compositions containing them
US4997836A (en) * 1988-11-11 1991-03-05 Takeda Chemical Industries, Ltd. Trisubstituted piperazine compounds, their production and use
US5510487A (en) * 1990-11-19 1996-04-23 G.D. Searle & Co. Retroviral protease inhibitors
DE122007000045I2 (de) * 1992-08-25 2011-07-21 Gd Searle Llc Gd Searle Llc Darunavir oder pharmazeutisch vertragliche Salze, Hydroxyethylaminosulfonamide verwendbar als InhibiEster oder Prodrugs davon. toren retroviraler Proteasen.
US5475138A (en) * 1994-07-07 1995-12-12 Pharm-Eco Laboratories Incorporated Method preparing amino acid-derived diaminopropanols
PL193686B1 (pl) * 1995-09-07 2007-03-30 Hoffmann La Roche Pochodne piperydyny, środki lecznicze zawierającepochodne piperydyny, sposoby wytwarzania tych pochodnych oraz zastosowanie pochodnych
WO1998033795A1 (en) 1997-02-04 1998-08-06 The Regents Of The University Of California Nanomolar, non-peptide inhibitors of cathepsin d
AU9740998A (en) 1997-09-08 1999-03-29 F. Hoffmann-La Roche Ag Piperidine derivatives against malaria
EP1034174B1 (en) * 1997-11-05 2003-08-13 Neurosearch A/S Azaring-ether derivatives and their use as nicotinic ach receptor modulators
DK1049700T3 (da) * 1998-01-21 2006-02-20 Millennium Pharm Inc Kemokinreceptorantagonister og fremgangsmåder til anvendelse deraf
GB9810671D0 (en) * 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
CA2336806A1 (en) * 1998-07-10 2000-01-20 Keith Russell N-substituted naphthalene carboxamides as neurokinin-receptor antagonists
US6274735B1 (en) 1998-08-10 2001-08-14 Hoffmann-La Roche Inc. Process and intermediates for preparation of substituted piperidines
US6440996B1 (en) * 1998-10-07 2002-08-27 Georgetown University Monomeric and dimeric heterocycles, and therapeutic uses thereof
GB9904786D0 (en) * 1999-03-02 1999-04-28 Merck Sharp & Dohme Therapeutic agents
CA2438318A1 (en) 2001-02-16 2002-08-29 Aventis Pharmaceuticals Inc. Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
WO2002076440A2 (en) 2001-03-23 2002-10-03 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
JP2004534017A (ja) * 2001-04-27 2004-11-11 バーテックス ファーマシューティカルズ インコーポレイテッド Baceのインヒビター

Also Published As

Publication number Publication date
US20040034031A1 (en) 2004-02-19
WO2003043987A3 (en) 2003-07-10
CO5580743A2 (es) 2005-11-30
GEP20074045B (en) 2007-02-26
TNSN04088A1 (en) 2006-06-01
RS54204A (sr) 2006-12-15
BR0214295A (pt) 2004-11-09
MXPA04004772A (es) 2005-06-06
NO20042580L (no) 2004-08-09
AU2002360403A1 (en) 2003-06-10
EP1448200A2 (en) 2004-08-25
WO2003043987A2 (en) 2003-05-30
HRP20040550A2 (en) 2006-11-30
CA2467749A1 (en) 2003-05-30
EA200400699A1 (ru) 2004-12-30
KR20050044533A (ko) 2005-05-12
IL162079A0 (en) 2005-11-20
US7338965B2 (en) 2008-03-04
NZ533158A (en) 2006-09-29
AP2004003052A0 (en) 2004-06-30
JP2005514362A (ja) 2005-05-19
IS7271A (is) 2004-05-19

Similar Documents

Publication Publication Date Title
ES2325140T3 (es) Amidas sustituidas con heterociclos como inhibidores de la calpaina.
RU2690489C2 (ru) Ингибиторы лейкотриен а4-гидролазы
AU2002320490B2 (en) N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds
NZ533158A (en) 3,4-Disubstituted, 3,5-disubstituted and 3,4,5-substituted piperidines and piperazines
JP4175885B2 (ja) セリンプロテアーゼインヒビター
EP1395551B1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
WO2004022523A2 (en) 1, 3-diamino-2-hydroxypropane prodrug derivatives
JP2005511735A (ja) 置換ヒドロキシエチルアミン
JP2006524255A (ja) ベンズアミド2−ヒドロキシ−3−ジアミノアルカン
WO2003027068A2 (en) Substituted amines for the treatment of neurological disorders
JP2005534614A (ja) アルツハイマー病治療のための置換アミノカルボキサミド
CA2556826A1 (en) Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
WO2005030709A1 (en) Novel sulfone amide derivatives capable of inhibiting bace
US20040039034A1 (en) Hydroxypropyl amides for the treatment of Alzheimer's disease
US20060014737A1 (en) Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
EP1537072A1 (en) Substituted aminoethers for the treatment of alzheimer s disease
JP2005505517A (ja) アルツハイマー病を治療するためのアミンジオール
JP2009511589A (ja) アリール−シクロプロピル誘導体のアスパルチルプロテアーゼ阻害剤を使用してアミロイドーシスを治療する方法
DE60219680T2 (de) Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit
KR100814092B1 (ko) 히스톤 디아세틸라제 저해활성을 갖는 알킬카바모일나프탈렌일옥시 옥테노일 하이드록시아마이드 유도체, 이의제조방법 및 이를 유효성분으로 하는 항암제용 약학조성물
CA2600074A1 (en) Novel cyclic aminophenylalkanoic acid derivative
JP2007509988A (ja) アルツハイマー病治療のためのヒドロキシプロピルアミド
CA2576782A1 (en) Methods of treatment of amyloidosis using substituted ethanolcyclicamine aspartyl protease inhibitors
JPWO2000061556A1 (ja) 含窒素複素環化合物並びにベンズアミド化合物およびそれを含んでなる医薬